OTTAWA, September 17th, 2021 – Spartan Bioscience Inc. (Spartan) announces today that its primary assets have been acquired by Genomadix Inc. (Genomadix) a new company formed to carry on Spartan’s mission.  Genomadix, based in Ottawa Canada, ensures that Spartan’s disruptive technology, and talented team of scientists, engineers and biotech professionals, remain in Canada and dedicated to realizing Spartan’s vision in enabling access to highly accurate molecular diagnostics to the masses outside of the confines of traditional laboratories.

“We are excited to have acquired Spartan’s disruptive technology platform, and are honored to be able to continue this noble mission to improve access to this life saving technology.  Genomadix is committed to delivering on quality and excellence while continuing to innovate in point of care diagnostics and testing in the field” says Steven Edgett, CEO of Genomadix Inc. Founded in 2005, Spartan has pioneered cutting-edge molecular diagnostic testing technology that provides individuals with accurate and rapid results, outside of the traditional laboratory. Its main product – widely considered to be the first of its kind developed and launched in Canada – is The Spartan Cube®, a portable, molecular analyzer. The Spartan Cube® uses polymerase chain reaction (PCR) technology to generate rapid, accurate test results, practically anywhere. 

“Closing this transaction ensures that all business operations will continue without disruption both in supporting our existing customers with products and services as well as aggressively moving forward on new product development efforts currently underway” Edgett added.
This acquisition closed on September 9th, 2021. 

About Spartan Bioscience Inc.

Founded in 2005, Spartan Bioscience Inc. (Spartan) is a Canadian biotechnology company in portable molecular diagnostic testing. The Spartan Cube® brings complete sample-to-result DNA testing to fields such as precision medicine, environmental water testing, and infectious diseases. Spartan’s technology has been published in prestigious medical journals including The Lancet and The New England Journal of Medicine and is used by expert organizations such as the Centers for Disease Control & Prevention (CDC) and Mayo Clinic. 

About Genomadix Inc

Genomadix Inc (Genomadix), founded in 2021 was incorporated after the assets of Genomadix were acquired on September 9th, 2021.  Genomadix continues to operate all business previously delivered by Spartan and is committed to the highest level of customer satisfaction and support in the delivery of the Genomadix Cube® and related sample to result molecular testing.   

For more information on Genomadix and the acquisition of Spartan assets please contact media@spartanbio.com.

Contacts

Media Relations: media@genomadix.com